Of note, lenalidomide triggers NK-cell activation and increases antibody-dependent cell cytotoxicity in patients with FL [11], suggesting that combination of lenalidomide with a PD-1/PD-L1 inhibitor could have synergistic effects on NK cell anti-tumor activity in these patients. This evidence concerns the gene CD274 and neoplasm.